New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
15:02 EDTMDTMedtronic says results from CRYSTAL AF trial met primary endpoint
Medtronic announced results from the CRYSTAL AF Clinical Trial, which found that continuous cardiac monitoring with the Reveal XT Insertable Cardiac Monitor was superior to standard care at detecting atrial fibrillation in patients who have had strokes of undetermined causes. Presented at a late-breaking science session at the American Stroke Association's International Stroke Conference, the randomized, global study met its primary endpoint by demonstrating that continuous monitoring with the Reveal ICM discovered AF in 6.4 times more patients than standard care at six months (p=0.0006). In addition, the Trial found that compared to standard care (including electrocardiograms, Holter monitors and other short-term diagnostic tests prescribed over the follow-up period), the Reveal ICM detected AF in 7.3 times more patients at 12 months (p<0.0001), and 8.8 times more patients at 36 months (p<0.0001). When followed for 36 months, 30 percent of the patients in the ICM arm had AF detected.
News For MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 11, 2014
09:05 EDTMDTMedtronic receives FDA approval for Attain Performa LV quadripolar leads
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use